Skip to main content

Table 1 Baseline characteristics

From: Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study

 

Survivors

Non-survivors

P

n = 39

n = 58

Age (years)

57 ± 16

66 ± 15

0.007

Male (%)

25 (64)

42 (72)

0.36

Weight (kg)

79 ± 14

76 ± 18

0.29

APACHE II

23 ± 5

24 ± 7

0.31

SAPS II

52 ± 9

57 ± 13

0.04

SOFA day 1

12 ± 3

12 ± 4

0.74

SOFA day 3

13 ± 4

14 ± 3

0.27

SOFA at start CVVH

13 ± 4

14 ± 3

0.27

Manifest bleeding (%)

18 (46)

24 (41)

0.65

Blood transfusion (%)

21 (54)

32 (55)

0.90

Reason of admission (%)

  

0.27

   Postoperative

18 (46)

18 (31)

   Respiratory insufficiency

10 (26)

25 (43)

   Cardiogenic shock

9 (23)

10 (17)

   After CPR

1 (3)

3 (5)

   CVVH

1 (3)

2 (3)

Reason of renal failure (%)

  

0.10

   Sepsis

8 (21)

14 (24)

   Ischemic

19 (49)

35 (60)

   Toxic

1 (3)

0

   Metabolic

2 (5)

0

   Auto-immune

2 (5)

1 (2)

   Unknown

3 (8)

3 (5)

   History of CKD

4 (10)

5 (9)

At start of CVVH

   

Creatinine (μmol/l)

364 ± 186

312 ± 233

0.28

Urea (mmol/l)

20.0 ± 7.2

21.1 ± 12.0

0.63

Potassium (mmol/l)

4.8 ± 0.8

4.5 ± 0.8

0.10

pH

7.33 ± 0.11

7.30 ± 0.10

0.12

Bicarbonate (mmol/l)

19.6 ± 3.9

18.6 ± 4.2

0.24

Lactate (mmol/l)

2.9 ± 2.2

4.3 ± 4.0

0.09

Diuresis (ml/day)

547 ± 709

601 ± 622

0.75

aPTT (sec)

50 ± 34

55 ± 30

0.51

PT-INR

1.63 ± 0.56

1.88 ± 0.82

0.14

Platelets (×109/l)

116 ± 75

107 ± 72

0.89

  1. Data are expressed as mean (±standard deviation) or number (percentage) of patients where appropriate. APACHE II Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; SAPS II: Simplified Acute Physiological Score; CVVH: continuous venovenous haemofiltration; ICU: intensive care unit; CPR: cardiopulmonary resuscitation; CKD: chronic kidney disease; aPTT: activated partial thromboplastin time; PT-INR: prothrombin time–international normalized ratio.